Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

48.58 -1.03 (-2.08%)
Streaming Delayed Price Updated: 11:08 AM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders
From Sarissa Capital Management LP
Via Business Wire
News headline image
Independent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders’ Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Independent Proxy Advisory Firm ISS Concludes That Sarissa Capital Has Made a Compelling Case for Change to the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Issues Presentation Highlighting the Need for Shareholder Representation on the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Where Alkermes Stands With Analysts ↗
 
Via Benzinga
News headline image
Alkermes Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Analyst Expectations for Alkermes's Future ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Alkermes ↗
 
Via Benzinga
News headline image
Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Capital Highlights Misleading Claims Made by Alkermes in Its Attempt to Thwart Shareholder Representation on the Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Alkermes Raises FY23 Outlook Following Arbitration Award from Janssen Agreements ↗
 
Via Benzinga
News headline image
Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders
From Sarissa Capital Management LP
Via Business Wire
News headline image
A Preview Of Alkermes's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 16, 2023 ↗
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
News headline image
Alkermes Earnings Preview ↗
 
Via Benzinga
Analyst Ratings for Alkermes ↗
 
Via Benzinga
News headline image
Alkermes Plans Separating Its Oncology Unit; Lifts FY22 Earnings Guidance ↗
 
Via Benzinga
News headline image
Alkermes Stock Sees Rising Relative Strength Rating ↗
The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77. 
Via Investor's Business Daily
News headline image
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
News headline image
Alkermes: Commercialization Program On Track, Sales Coming In Strong ↗
The bigger biotechs have done a good job lately, with solid earnings to date. Speaking of which, Alkermes plc has recently exceeded estimates. Let's take a closer look at the company's performance. 
Via Talk Markets
News headline image
Alkermes Stock Sees Rising Relative Price Strength ↗
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86. 
Via Investor's Business Daily
News headline image
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out ↗
Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev. 
Via Investor's Business Daily
News headline image
Alkermes's Return On Capital Employed Insights ↗
Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q3 sales of $252.36 million. Earnings fell to a loss of $63.97 million, resulting in a 112.28% decrease from last quarter. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Recap: Alkermes Q3 Earnings ↗
Alkermes (NASDAQ:ALKS) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Alkermes missed estimated... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday ↗
Wedbush raised Domino's Pizza, Inc. (NYSE: DPZ) price target from $370 to $400. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Domino's shares rose 10.4% to close at $333.26... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022 ↗
  
Via Benzinga
News headline image
Looking Into Alkermes's Return On Capital Employed ↗
According to data from Benzinga Pro, during Q2, Alkermes's (NASDAQ:ALKS) reported sales totaled $276.22 million. Despite a 16.06% increase in earnings, the company posted a loss of $30.14 million. 
Via Benzinga
News headline image
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.